What is the likely diagnosis and recommended treatment for a 55-year-old woman presenting with anemia (hemoglobin 8.5 g/dL), leukopenia (total leukocyte count 2700/µL) and low neutrophils, lymphocytes, and monocytes?

Likely Diagnosis: Pancytopenia - Suspect Myelodysplastic Syndrome (MDS) or Bone Marrow Failure

This 55-year-old woman with pancytopenia (anemia with Hb 8.5 g/dL, leukopenia with TLC 2700/µL, and low neutrophils, lymphocytes, and monocytes) requires immediate bone marrow examination to differentiate between myelodysplastic syndrome, aplastic anemia, or other bone marrow failure syndromes—this is the critical first diagnostic step that will determine all subsequent treatment.

Diagnostic Workup Algorithm

Immediate Essential Tests:

• Bone marrow aspiration and biopsy with cytogenetics - This is non-negotiable and must be done first 1, 2
• Peripheral blood smear review for dysplasia, blasts, or abnormal cells
• Reticulocyte count to assess bone marrow response
• Vitamin B12, folate, and iron studies (ferritin, TIBC, serum iron) 3, 4
• Liver and renal function tests
• Thyroid function tests (autoimmune thyroid disease is common in this demographic) 3
• Autoimmune workup: ANA, anti-dsDNA, rheumatoid factor 3
• Viral serologies: HIV, hepatitis B/C, CMV, EBV
• Serum erythropoietin level 1

Critical Point on Iron Deficiency:

While iron deficiency anemia is extremely common in 55-year-old women 5, and can even cause leukopenia 6, 3, 7, isolated iron deficiency does NOT cause pancytopenia with low lymphocytes and monocytes. However, check iron studies as this may be a contributing factor requiring correction 3.

Most Likely Diagnoses Based on Presentation:

1. Myelodysplastic Syndrome (MDS) - Most Probable

This age and presentation pattern strongly suggests lower-risk MDS 1, 2. The combination of:

• Age 55 years (typical MDS demographic)
• Pancytopenia affecting all three cell lines
• Moderate anemia (Hb 8.5 g/dL)
• Leukopenia with multilineage cytopenia

Risk stratification after bone marrow: Use IPSS-R scoring system to determine lower-risk vs higher-risk MDS 1, 2

2. Aplastic Anemia - Second Consideration

Particularly if bone marrow shows hypocellularity 8

3. Autoimmune Causes - Third Consideration

Given that autoimmunity accounts for >50% of isolated leukopenia cases in this demographic 3, and autoimmune thyroid disease affects 21.8% of such patients 3

Treatment Algorithm Based on Final Diagnosis:

If Lower-Risk MDS (IPSS Low/Intermediate-1):

For Anemia Management:

1. First-line if serum EPO <500 mU/mL: Erythropoiesis-stimulating agents (ESAs)

   • Recombinant EPO 30,000-80,000 units weekly OR darbepoetin 150-300 μg weekly
   • Add G-CSF if needed for enhanced response
   • Expect response within 8-12 weeks 1

2. If del(5q) cytogenetic abnormality present: Lenalidomide 10 mg/day, 3 weeks out of 4 1, 2

   • 60-65% response rate
   • Monitor closely for neutropenia/thrombocytopenia (occurs in 60% of patients)

3. Second-line options after ESA failure:

   • Luspatercept (if SF3B1 mutation or ring sideroblasts present) 2
   • Hypomethylating agents (azacitidine or decitabine) 1, 2
   • Immunosuppressive therapy with ATG if: age <65 years, hypocellular marrow, HLA-DR15 positive, or short transfusion history 1, 9

For Neutropenia:

• G-CSF can be added if neutropenia is severe or infections develop 1, 2
• Prophylactic antibiotics if neutrophils persistently <500/µL

If Higher-Risk MDS (IPSS Intermediate-2/High):

Treatment priority:

1. If age <65-70 years and fit: Consider allogeneic stem cell transplantation (only curative option) 1, 10, 2
2. If not transplant candidate: Hypomethylating agents (azacitidine preferred - shows survival benefit) 1, 8, 1, 8

If Aplastic Anemia:

Treatment depends on severity:

• Severe aplastic anemia: Immunosuppressive therapy (ATG + cyclosporine) or allogeneic transplant if suitable donor available 8
• Moderate aplastic anemia: Immunosuppressive therapy first-line

If Autoimmune Cause Identified:

• Treat underlying autoimmune condition
• Consider immunosuppressive therapy
• Correct thyroid dysfunction if present 3

Supportive Care (Applies to All):

Transfusion thresholds:

• RBC transfusion: Maintain Hb >8 g/dL (consider >9-10 g/dL if symptomatic or comorbidities present) 11, 8
• Platelet transfusion: Maintain platelets >10,000/µL prophylactically (>20,000/µL if bleeding risk factors) 11

Iron chelation: If serum ferritin >1000 ng/mL after chronic transfusions 2

Infection prophylaxis:

• Antifungal prophylaxis (posaconazole or itraconazole) if neutropenic 11
• Antibacterial prophylaxis with fluoroquinolones if severe neutropenia

Critical Pitfalls to Avoid:

1. Do NOT delay bone marrow examination - treating empirically without tissue diagnosis risks missing acute leukemia or other aggressive malignancies
2. Do NOT assume this is just iron deficiency - while common in this demographic, pancytopenia requires bone marrow evaluation 3
3. Do NOT start ESAs if serum EPO >500 mU/mL - response rate is <10% 1, 9
4. Do NOT use lenalidomide without confirming del(5q) in non-del(5q) MDS - response rates are much lower 1
5. Monitor for progression - lower-risk MDS can transform to acute myeloid leukemia; regular follow-up with blood counts every 3 months is essential 12, 1

The bone marrow examination with cytogenetics is the cornerstone that determines everything else - proceed urgently with this diagnostic test.